{
  "id": "5c73ad0b7c78d69471000093",
  "type": "yesno",
  "question": "Does simvastatin improve outcomes of aneurysmal subarachnoid hemorrhage?",
  "ideal_answer": "No. Simvastatin showed no benefits in decreasing the incidence of vasospasm, DCI, or all-cause mortality after aneurysmal subarachnoid hemorrhage. Patients with aneurysmal subarachnoid hemorrhage should not be treated routinely with simvastatin during the acute stage.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28661267",
    "http://www.ncbi.nlm.nih.gov/pubmed/27160932",
    "http://www.ncbi.nlm.nih.gov/pubmed/28169856",
    "http://www.ncbi.nlm.nih.gov/pubmed/26587185",
    "http://www.ncbi.nlm.nih.gov/pubmed/28966073",
    "http://www.ncbi.nlm.nih.gov/pubmed/25516195",
    "http://www.ncbi.nlm.nih.gov/pubmed/26285662"
  ],
  "snippets": [
    {
      "text": "Randomized controlled trials have shown that simvastatin and intravenous magnesium do not prevent DCI or improve functional outcomes after aneurysmal subarachnoid hemorrhage (aSAH).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28169856",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusions Simvastatin showed no benefits in decreasing the incidence of vasospasm, DCI, or all-cause mortality after aneurysmal SAH. We conclude that patients with SAH should not be treated routinely with simvastatin during the acute stage.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28661267",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We found no statistically significant effects on vasospasm detected by transcranial cerebral Doppler (relative risk [RR], 0.91; 95% confidence interval [CI], 0.55-1.49), delayed cerebral ischemia (DCI) (RR, 0.85; 95% CI, 0.63-1.14), or all-cause mortality (RR, 1.02; 95% CI, 0.67-1.54).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28661267",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Simvastatin might be beneficial to the patients with aneurysmal subarachnoid hemorrhage. However, the results remained controversial. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28966073",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Compared to control intervention, simvastatin intervention was found to have no influence on delayed ischaemic deficit, delayed cerebral infarction, mRS\u22642, vasospasm, ICU stay, hospital stay, and mortality in patients with acute aneurysmal subarachnoid hemorrhage.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28966073",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Current evidence does not support prophylactic use of clazosentan, magnesium, or simvastatin. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27160932",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, acute simvastatin treatment was not shown to be beneficial in neurological outcome using modified Rankin Scale.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26285662",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: The current study does not support that acute simvastatin treatment improves cognitive outcome after aneurysmal subarachnoid hemorrhage.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26285662",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: This study demonstrated that 80 mg simvastatin treatment was effective in preventing cerebral vasospasm after aneurysmal SAH, but did not improve the clinical outcome in Korean patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26587185",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "High-Dose Simvastatin Is Effective in Preventing Cerebral Vasospasm after Aneurysmal Subarachnoid Hemorrhage: A Prospective Cohort Study in Korean Patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26587185",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS\nThe current study does not support that acute simvastatin treatment improves cognitive outcome after aneurysmal subarachnoid hemorrhage.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26285662",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\nHigh-dose simvastatin treatment should not be prescribed routinely for aneurysmal subarachnoid hemorrhage.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516195",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Randomized controlled trials have shown that simvastatin and intravenous magnesium do not prevent DCI or improve functional outcomes after aneurysmal subarachnoid hemorrhage (aSAH).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28169856",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\nCompared to control intervention, simvastatin intervention was found to have no influence on delayed ischaemic deficit, delayed cerebral infarction, mRS\u22642, vasospasm, ICU stay, hospital stay, and mortality in patients with acute aneurysmal subarachnoid hemorrhage.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28966073",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS The current study does not support that acute simvastatin treatment improves cognitive outcome after aneurysmal subarachnoid hemorrhage.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26285662",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS High-dose simvastatin treatment should not be prescribed routinely for aneurysmal subarachnoid hemorrhage.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516195",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS Compared to control intervention, simvastatin intervention was found to have no influence on delayed ischaemic deficit, delayed cerebral infarction, mRS\u22642, vasospasm, ICU stay, hospital stay, and mortality in patients with acute aneurysmal subarachnoid hemorrhage.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28966073",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There were also no differences in DID, delayed cerebral infarction, favorable mRS outcome, and MMSE scores, and MMSE-assessed cognitive impairment between both groups.<br><b>CONCLUSIONS</b>: The current study does not support that acute simvastatin treatment improves cognitive outcome after aneurysmal subarachnoid hemorrhage.<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26285662",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}